Become a Member

Track your favourite stocks
Create & monitor portfolios
Daily portfolio value

Company	Chg	Chg %
Quickpicks
£	%
Add shares to your quickpicks to display them here!

Hutchmed (HCM) Share News

UK earnings, trading statements calendar - next 7 days

26th Feb 2026 14:45

Hutchmed China hails lung cancer trial results published in Lancet

14th Jan 2026 12:06

(Alliance News) - Hutchmed China Ltd on Wednesday said the results from its SACHI phase-three lung cancer trial have been published in medical journal the Lancet. Read More

Hutchmed China hails sovleplenib results for form of anaemia in China

7th Jan 2026 11:41

(Alliance News) - Hutchmed China Ltd on Wednesday announced topline results of a phase 3 trial of its selective small molecule inhibitor sovleplenib, in a form of anaemia. Read More

Hutchmed China kicks off phase three stage of pancreatic cancer trial

5th Jan 2026 10:45

(Alliance News) - Hutchmed China Ltd on Monday said it has started the phase three part of a trial evaluating surufatinib and camrelizumab for the treatment of pancreatic cancer in China. Read More

Hutchmed savolitinib NDA for gastric cancer accepted in China

30th Dec 2025 11:21

(Alliance News) - Hutchmed China Ltd on Tuesday said Chinese regulators have accepted and granted priority review to its new drug application for savolitinib to treat certain patients with advanced gastric cancer, marking another regulatory step forward for the targeted therapy. Read More

Hutchmed drug gains China priority review for bile duct cancer

29th Dec 2025 10:51

(Alliance News) - Hutchmed China Ltd on Monday said Chinese regulators have accepted a new drug application for its cancer treatment fanregratinib and granted it priority review status. Read More

Hutchmed China kicks off clinical development of ATTC candidate

17th Dec 2025 13:25

(Alliance News) - Hutchmed China Ltd on Wednesday said it has begun the global phase one clinical development programme for its targeted cancer therapy for patients with solid tumours. Read More

Hutchmed drugs stay on NRDL; Tazverik added to new insurance list

8th Dec 2025 11:15

(Alliance News) - Hutchmed China Ltd on Monday said several of its oncology medicines will continue to be reimbursed under China's national insurance scheme next year, while one of its newer cancer drugs has secured a place on the country's first-ever commercial insurance drug list. Read More

Hutchmed completes Saffron trial enrolment, results due 2026

5th Nov 2025 11:48

(Alliance News) - Hutchmed China Ltd on Wednesday said patient enrolment has been completed for its phase 3 Saffron trial evaluating the combination of Orpathys and Tagrisso in certain lung cancer patients, with topline results expected in the first half of 2026. Read More

Hutchmed China CFO Cheng is interim CEO as CEO Su takes health leave

26th Aug 2025 09:14

(Alliance News) - Hutchmed China Ltd on Tuesday said Chief Executive Officer Weiguo Su will take a leave of absence for health reasons. Read More

Hutchmed China completes enrollment for phase three lung cancer trial

20th Aug 2025 10:55

(Alliance News) - Hutchmed China Ltd on Wednesday said it has completed patient enrollment of Sanovo, a phase three trial of Orpathys and Tagrisso. Read More

Hutchmed China interim profit jumps on joint venture stake disposal

7th Aug 2025 14:33

(Alliance News) - Hutchmed China Ltd on Thursday reported a jump in profit during the first half of its current financial year, and forecasts a full-year decline in its key Oncology/Immunology segment. Read More

UK earnings, trading statements calendar - next 7 days

31st Jul 2025 14:25

Hutchmed reports progress in late-stage lung cancer trial

2nd Jun 2025 11:19

(Alliance News) - Hutchmed China Ltd on Monday said its combination therapy for a specific form of advanced lung cancer significantly delayed disease progression compared to chemotherapy, based on phase III trial data presented at a major oncology conference. Read More

UK shareholder meetings calendar - next 7 days

6th May 2025 14:14

UK shareholder meetings calendar - next 7 days

2nd May 2025 14:35

AIM WINNERS & LOSERS: Celebrus revenue to fall short of guidance

22nd Apr 2025 10:53

(Alliance News) - The following stocks are the leading risers and fallers on AIM on Tuesday. Read More

LONDON MARKET OPEN: FTSE 100 opens green as gold reaches USD3,500 mark

22nd Apr 2025 09:03

(Alliance News) - London's FTSE 100 opened higher on Tuesday following the long Easter weekend, as the gold price rallies in response to a weakening US dollar and efforts by US President Donald Trump to potentially force out the Federal Reserve chair. Read More

Hutchmed China completes enrolment for gastric cancer drug trial

22nd Apr 2025 08:32

(Alliance News) - Hutchmed China Ltd on Tuesday said it has completed patient enrolment for a phase II registration trial of savolitinib, targeting gastric cancer in patients with MET gene amplification. Read More

LONDON BRIEFING: DCC to sell Healthcare arm, Ricardo "well-positioned"

22nd Apr 2025 07:49

(Alliance News) - London's FTSE 100 was called higher on Tuesday following the long Easter weekend as the gold price reaches a new record high, while US investors remain cautious amid US President Donald Trump's threats to oust the Federal Reserve chair. Read More

FTSE 100 Latest

Value10,910.55

Change63.85